| Old Articles: <Older 40281-40290 Newer> |
|---|
 |
The Motley Fool
February 17, 2010
Brian Orelli |
Execute Well or You're Out Genzyme needs to show investors that it can rebuild.   |
The Motley Fool
February 17, 2010
Rick Aristotle Munarriz |
Say Farewell to Stock Splits Apple and Google keep climbing, with no stock split in sight. |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
The Motley Fool
February 17, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Dahlman Rose downgrade drops Transocean down a hole. |
The Motley Fool
February 17, 2010
Anders Bylund |
How 3-D Tech Is Saving Hollywood "Avatar" and Zeus himself are paving the way for a happier, more profitable Hollywood. |
The Motley Fool
February 17, 2010
Mike Pienciak |
Can You Stomach This Consumer Icon's Shares? Kraft holds long-term promise, but there will be bumps along the way. |
The Motley Fool
February 17, 2010
Russ Krull |
Fossil Comes to Life The fashionable outfitter unearths impressive Q4 earnings. |
The Motley Fool
February 17, 2010
Tim Beyers |
Penalize the iPhone! Research In Motion pitches efficiency. |
The Motley Fool
February 17, 2010
Tim Beyers |
You Blew It, eBay Look where Skype is now. |
The Motley Fool
February 17, 2010
Brian Orelli |
$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%. |
| <Older 40281-40290 Newer> Return to current articles. |
